View Older Stories View More Recent Stories

Jul 5, 2023 08:00AM Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
Jun 28, 2023 08:31AM Biora Therapeutics (BIOR) Announces New Patents for NaviCap
Jun 28, 2023 08:30AM Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
Jun 26, 2023 06:00AM Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
Jun 14, 2023 04:05PM Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules
Jun 13, 2023 08:00AM Biora Therapeutics (BIOR) Announces 1.5M Share Direct Offering at $5.30/sh
Jun 13, 2023 08:00AM Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jun 8, 2023 09:00AM Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
May 15, 2023 04:05PM Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 8, 2023 09:00AM Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
May 1, 2023 09:00AM Biora Therapeutics (BIOR) Appoints Ariella Kelman as Chief Medical Officer
May 1, 2023 09:00AM Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
May 1, 2023 09:00AM Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
Apr 20, 2023 04:46PM Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
Apr 20, 2023 04:46PM Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
Mar 30, 2023 04:01PM Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Mar 30, 2023 04:01PM Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Mar 23, 2023 09:00AM Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
Mar 23, 2023 09:00AM Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
Feb 23, 2023 09:03AM Biora Therapeutics (BIOR) Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Feb 23, 2023 09:00AM Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Feb 23, 2023 09:00AM Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Feb 16, 2023 09:00AM Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
Feb 16, 2023 09:00AM Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
Jan 19, 2023 04:05PM Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Jan 19, 2023 04:05PM Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Jan 9, 2023 09:00AM Biora Therapeutics (BIOR) Receives Pre-IND Feedback from FDA, Provides Update on Key Programs for 2023
Jan 9, 2023 09:00AM Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
Jan 9, 2023 09:00AM Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
Dec 30, 2022 09:00AM Biora Therapeutics (BIOR) Announces 1:25 Reverse Stock Split
Dec 30, 2022 09:00AM Biora Therapeutics (BIOR) Announces 1:25 Reverse Stock Split
Dec 30, 2022 09:00AM Biora Therapeutics Announces Reverse Stock Split
Dec 30, 2022 09:00AM Biora Therapeutics Announces Reverse Stock Split
Dec 8, 2022 04:05PM Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
Dec 8, 2022 04:05PM Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
Nov 29, 2022 09:00AM Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Nov 29, 2022 09:00AM Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Nov 14, 2022 04:01PM Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Nov 14, 2022 04:01PM Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Nov 7, 2022 04:15PM Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
Nov 7, 2022 04:15PM Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
Nov 7, 2022 08:08AM Biodrain Medical (BIOR) Prices 32.5M Share Direct Offeirng at $0.30/sh
Nov 7, 2022 08:06AM Biora Therapeutics Announces $9.75 Million Direct Offering
Nov 7, 2022 08:06AM Biora Therapeutics Announces $9.75 Million Direct Offering
Oct 27, 2022 09:00AM Biodrain Medical, Inc. (BIOR) Sells Cell-Free DNA Patent Rights
Oct 27, 2022 09:00AM Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
Oct 27, 2022 09:00AM Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
Oct 25, 2022 09:00AM Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients
Oct 25, 2022 09:00AM Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients
Oct 24, 2022 09:00AM Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022
View More Recent Stories View Older Stories